Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Special Survey for Long Term Application

This study has been completed.
Sponsor:
Information provided by:
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
NCT01516229
First received: January 19, 2012
Last updated: June 26, 2012
Last verified: January 2012

January 19, 2012
June 26, 2012
May 1997
March 2006   (final data collection date for primary outcome measure)
Incidence of adverse drug reactions (ADRs) [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01516229 on ClinicalTrials.gov Archive Site
Treatment evaluation using the Foundation for Growth Science's Criteria for Treatment Continuation: Definitely effective, effective, ineffective or definitely ineffective [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Special Survey for Long Term Application
Specific Survey of Norditropin® in Achondroplasia: Survey for Long-term Application

This study is conducted in Japan. The aim of this study is to assess the incidence rate of adverse drug reactions (ADRs) when using somatropin (Norditropin®) for treatment of for achondroplasia without epiphyseal line closure under normal clinical practice conditions.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

Patients being treated with somatropin for achondroplasia without epiphyseal line closure

  • Genetic Disorder
  • Achondroplasia
Drug: somatropin
Prescription of somatropin at the discretion of the physician
Somatropin
Intervention: Drug: somatropin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
395
March 2007
March 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Achondroplasia without epiphyseal line closure
Both
1 Year to 15 Years
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
NCT01516229
GH-1941
No
Public Access to Clinical Trials, Novo Nordisk A/S
Novo Nordisk A/S
Not Provided
Study Director: Masayuki Senda Novo Nordisk Pharma Ltd.
Novo Nordisk A/S
January 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP